Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;25(16):2000421.
doi: 10.2807/1560-7917.ES.2020.25.16.2000421.

Serological Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), March 2020

Affiliations
Free PMC article

Serological Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), March 2020

Ranawaka Apm Perera et al. Euro Surveill. .
Free PMC article

Abstract

BackgroundThe ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making.AimOur objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies.MethodsWe developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT90) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls.ResultsIgG and IgM RBD ELISA, MN and PRNT90 were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT90 tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test.ConclusionUsing IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT90, is a valid approach for large-scale sero-epidemiology studies.

Keywords: COVD19; ELISA; SARS-CoV-2; neutralization; receptor binding domain; serology.

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Antibody responses of the COVID-19 patient cohort in relation to duration of illness, Hong Kong, March 2020 (n = 24 patients, 51 sera)
Figure 2
Figure 2
Kinetics of antibody response in individual patients with SARS-CoV-2 infection by days after illness onset, Hong Kong, March 2020 (n = 17 patients)
Figure 3
Figure 3
Correlation between the ELISA test results and microneutralisation and plaque reduction neutralisation results in COVID-19 patients, Hong Kong, March 2020 (n = 24 patients, 51 sera)
Figure 4
Figure 4
Correlation between microneutralisation and IgG ELISA in pairs of plasma and serum specimens collected on the same day from COVID-19 patients, Hong Kong, March 2020 (n = 16 pairs of serum and plasma)

Similar articles

See all similar articles

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Word Health Organization (WHO). Coronavirus disease 2019 (COVID-19): Situation report 92. Geneva: WHO. [Accessed: 22 Apr 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200421-sitrep-92-covid-19.pdf?sfvrsn=38e6b06d_4
    1. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. Swiss Med Wkly. 2020;150:w20203. 10.4414/smw.2020.20203 - DOI - PubMed
    1. Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, Shen AL, et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis. 2010;51(10):1184-91. 10.1086/656740 - DOI - PMC - PubMed
    1. Wong JY, Kelly H, Ip DK, Wu JT, Leung GM, Cowling BJ. Case fatality risk of influenza A (H1N1pdm09): a systematic review. Epidemiology. 2013;24(6):830-41. 10.1097/EDE.0b013e3182a67448 - DOI - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

Feedback